Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An announcement from Hansoh Pharmaceutical Group Company Limited ( (HK:3692) ) is now available.
Hansoh Pharmaceutical Group Company Limited has announced that its self-developed HS-20118 tablets have received Clinical Trial Approval from China’s National Medical Products Administration. This approval allows the company to proceed with clinical trials for the treatment of moderate to severe plaque psoriasis, potentially enhancing its position in the pharmaceutical industry and offering new treatment options for patients.
The most recent analyst rating on (HK:3692) stock is a Buy with a HK$22.06 price target. To see the full list of analyst forecasts on Hansoh Pharmaceutical Group Company Limited stock, see the HK:3692 Stock Forecast page.
More about Hansoh Pharmaceutical Group Company Limited
Hansoh Pharmaceutical Group Company Limited is a pharmaceutical company incorporated in the Cayman Islands, focusing on the development of innovative drugs. The company operates in the healthcare industry, with a market focus on creating treatments for various medical conditions.
Average Trading Volume: 12,089,628
Technical Sentiment Signal: Buy
Current Market Cap: HK$157.9B
Learn more about 3692 stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue